There is barely any information about the prognostic significance of FLT3 expression and mutational status in cytogenetically distinct subgroups of acute lymphoblastic leukemia (ALL). We analyzed the presence of FLT3-tyrosine kinase domain (TKD) and FLT3-internal tandem duplication (ITD) mutations as well as FLT3 expression levels in 54 newly diagnosed patients with B-ALL (n ¼ 49) or T-ALL (n ¼ 5). All B/T-ALL samples tested negative for the presence of FLT3-TKD or FLT3-ITD. None of the T-ALL and E2A-PBX1 þ B-ALL overexpressed FLT3. In contrast, mainly MLL-AF4 þ B-ALL but also ETV6-RUNX1 þ , BCR-ABL þ or B-ALL displaying normal cytogenetics exhibited significantly higher FLT3 expression levels than normal bone marrow, supporting that aberrantly increased transcription of FLT3, rather than activating FLT3 mutations, contributes to the pathogenesis of these B-ALL. Using the median FLT3 expression as cut-off value we found that high-level FLT3 expression is associated with an extremely poor 1-year overall survival (OS; 0 vs 71%; P ¼ 0.002) and disease-free survival (DFS; 0 vs 43%; P ¼ 0.03) in MLL-AF4 þ B-ALL but not in MLL-germline B-ALL. Cox regression analysis with OS/DFS as end points showed that age414 years and high-level FLT3 expression were independent prognostic factors when all ALL patients were analyzed together. Importantly, when the MLL-AF4 þ B-ALL subgroup was analyzed separately, high-level FLT3 expression was the only independent prognostic factor for OS and treatment outcome. These findings indicate that high FLT3 expression identifies MLL-AF4 þ ALL patients at very high risk of treatment failure and poor survival, emphasizing the value of ongoing/future clinical trials for FLT3 inhibitors. Keywords: FLT3 mutations; FLT3 expression; MLL-AF4; B-ALL; T-ALL; fusion genes INTRODUCTION MLL-AF4 leukemogenesis has been particularly difficult to model and bona fide MLL-AF4 disease human models do not exist. Our current understanding of transformation by MLL-AF4 and its mode of action comes from murine models in which leukemias do not recapitulate the human disease faithfully. Existing murine models of MLL-AF4 acute leukemia have shown an extraordinary long latency period before overt disease develops, suggesting that additional genetic insults are required to generate leukemia.
INTRODUCTION
MLL-AF4 leukemogenesis has been particularly difficult to model and bona fide MLL-AF4 disease human models do not exist. Our current understanding of transformation by MLL-AF4 and its mode of action comes from murine models in which leukemias do not recapitulate the human disease faithfully. Existing murine models of MLL-AF4 acute leukemia have shown an extraordinary long latency period before overt disease develops, suggesting that additional genetic insults are required to generate leukemia. [1] [2] [3] [4] Gene expression profiling showed that the FMS-related tyrosine kinase-3 (FLT3) is highly expressed in MLL-rearranged acute lymphoblastic leukemia (ALL), 5 leading to the characterization of FLT3 mutations as potential secondary cooperating events. 6 Accordingly, Ono et al. 7 and Yamaguchi et al. 8 have reported that constitutively activating FLT3 mutations cooperate with MLL-ENL and MLL-AF4, respectively, to induce leukemia in murine models.
Although multiple studies have shown that activating mutations of FLT3 are common in AML, [9] [10] [11] there is controversy about the presence of such mutations among different subtypes of ALL. Several groups reported the presence of FLT3/tyrosine kinase domain (TKD) mutations in 3-20% of MLL-rearranged ALLs, 6, [12] [13] [14] whereas Stam et al. 15, 16 together with Bardini et al., 17, 18 using high-resolution genomic analysis, showed that FLT3 mutations in MLL-rearranged ALLs do not occur. Despite this emerging controversy, FLT3 is consistently highly expressed in MLLrearranged ALL, and therefore it is not fully resolved whether the constitutive activation of FLT3 in MLL-rearranged ALL is due to the presence of activating FLT3 mutations, or simply due to a transcriptional increased expression of FLT3 in an attempt to provide blast cells with survival and proliferative advantage. The latter has been recently suggested by Guenther et al., 19 by showing through elegant studies that FLT3 may be a direct target of MLL-AF4. 
MATERIALS AND METHODS Patients
Bone marrow samples from 54 newly diagnosed untreated patients with B-ALL (n ¼ 49) or T-ALL (n ¼ 5) were studied. Diagnosis of the different B-cell malignancies was based on clinical, morphologic, immunophenotypic, cytogenetic and molecular criteria according to the WHO classification. 11, 20 Acute leukemias were cytogenetically grouped as follows:
and T-ALL (n ¼ 5). Table 1 summarizes the diagnosis, cytogenetics and age for each patient. Median age for each group was 18 ± 17 for MLL-AF4 þ B-ALL, 5.3 ± 3 for ETV6-RUNX1 þ B-ALL, 44 ± 20 for BCR-ABL p190 þ B-ALL, 23±8 for E2A-PBX1 þ B-ALL, 6.7±3 for cytogenetically normal B-ALL and 27±19 for T-ALL. Ten normal bone marrow (NBM) samples were obtained from healthy volunteers and used as negative controls for FLT3 mutations and as calibrator for FLT3 gene expression. In all cases, informed consent according to the Local Ethics Committee of the University Hospital was given prior to entering the study.
RNA extraction and cDNA synthesis RNA extraction and reverse transcription was performed using the Europe against Cancer Group (EAC) protocol. 21 Briefly, 1 mg of total RNA was added to a 20-ml volume containing random hexamers as primers and 100 U of SuperScript RNase H reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The mixture was incubated at 42 1C for 60 min, followed by 3 min at 99 1C and 2 min at 4 1C. Aliquots were stored at À 80 1C prior to further analysis.
Determination of FLT3 mutation status FLT3-ITD was examined by amplification of the juxtamembrane domain spanning exons 14 and 15, as previously described. 22 To obtain the size and the relative level of mutations, real-time PCR was performed using a fluorescently-labeled primer with 6-FAM. Products were analyzed by Genescan analysis on a 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) (Supplementary Figure S1A) . To detect point mutations in codon D835 or deletions of codon I836, the restriction fragment length polymorphism-mediated PCR assay was used by amplifying the exon 20 of the FLT3 tyrosine kinase domain 22 (Supplementary Figure S1B) . In all cases, a confirmatory sequencing analysis of the amplified products was performed with the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems).
Quantification of FLT3 gene expression
The quantification of FLT3 gene was performed using the Step One Plus Real-Time PCR System and TaqMan Gene Expression Assays (Applied Biosystems) according to the manufacturer 0 s instructions. The assay IDs were: Hs00245445_m1 (ABL1, as control gene) and Hs00174690_m1 (FLT3). Relative quantification was calculated using the equation 2 À DDCt , where DCt ¼ Ct FLT3 -Ct ABL1 and DDCt ¼ DCt PATIENT -DCt HEALTHY BM as previously described. 23 In addition, FLT3 gene expression of 10 BM samples from healthy volunteers was used as a calibrator.
Statistical Analysis
The association between variables was analyzed by the w 2 -square and the Fisher 0 s exact tests for categorical variables and by the Student 0 s t-test or the Mann-Whitney U-test for continuous variables. In addition, a Kruskal-Wallis test was also used to compare the relative gene expression between different ALL cytogenetic subgroups. The probability of disease-free (DFS) and overall survival (OS) was estimated according to the Kaplan-Meier method, 24 and the log-rank test was used to evaluate differences between survival distributions. OS was calculated from the date of diagnosis to the date of death or last follow-up, and DFS was calculated from the date of complete remission achievement to the date of relapse, death or last follow-up of the patient in continuous complete remission. The Cox regression model was used to assess the predictive value of multiple variables at diagnosis in relation to OS and DFS in multivariate analysis. The parameters were considered either as continuous or as categorical variables and only those reaching a P value o0.1 in the respective univariate analysis were included. 24, 25 All P values were considered significant when o0.05. These analyses were performed using the SPSS 15.0 statistical software package (SPSS Inc., Chicago, IL, USA).
RESULTS
Absence of FLT3-TKD/ITD mutations in cytogenetically distinct groups of B-and T-ALL By means of real-time PCR followed by Genescan analysis of PCR products and restriction fragment length polymorphism-mediated PCR assay, we determined the FLT3 mutational status of 54 newly diagnosed untreated patients with B-ALL (n ¼ 49) or T-ALL (n ¼ 5). Neither point mutation/deletion in codons D835/I836 of the juxtamembrane TKD nor ITD of the FLT3 locus could be detected in any case, regardless of the clinical subgroup (Table 1 and Supplementary Figure S1 ).
FLT3 expression varies among cytogenetically distinct groups of ALL We then analyzed the FLT3 gene expression relative to ABL1 and normalized against the FLT3 expression in NBM. The expression of FLT3 varied between cytogenetically distinct groups of ALLs (Po0.0001) ( Figure 1 ). The lowest FLT3 expression level was found in E2A-PBX1 þ B-ALLs (mean: 1.4 ± 0.7) and T-ALLs (mean: 0.9 ± 0.6). In contrast, patients with ETV6-RUNX1 þ , BCR-ABL p190 þ or cytogenetically normal B-ALL displayed a FLT3 expression level 8.8-, 7.7-and 16-fold higher than NBM ( Figure 1 ). Interestingly, MLL-AF4 þ B-ALLs showed the highest FLT3 expression (37-fold higher than NBM), confirming that very high constitutive expression of FLT3 is a hallmark event in MLL-AF4 þ ALLs. The increased expression of FLT3 gene in the absence of FLT3 mutations suggests that constitutively activated FLT3 expression is a result of aberrantly increased transcription of FLT3 and it is not due to FLT3 activating mutations.
FLT3 expression level is a robust prognostic factor in MLL-AF4 þ B-ALL but not in MLL-germline ALL We analyzed whether FLT3 expression is a prognostic factor for OS and DFS in B-ALL patients using the median FLT3 expression as the cut-off value to divide all patients into two subgroups expressing high or low levels of FLT3 ( Figure 2 ). When all the ALL cases were analyzed together (regardless of the cytogenetic and phenotypic subgroup) we found that high-level FLT3 expression was associated with a slightly lower OS (P ¼ 0.224) but did not associate with significantly poor treatment outcome (DFS; P ¼ 0.491) (Figures 2a and b) . The 5-year OS estimate is 48% for patients expressing high levels of FLT3 compared with 65% for patients displaying low-level FLT3 expression (Figure 2a) . However, the 5-year DFS estimate is 58% for high-level FLT3 patients compared with 60% for low-level FLT3 patients (Figure 2b) .
Interestingly, when B-ALL patients were analyzed as MLL-AF4 þ vs MLL-germline cohorts, FLT3 expression was not a prognostic factor for MLL-germline ALL but for MLL-AF4 þ B-ALLs (Figures 2c  and d ). MLL-AF4 þ patients with high-level FLT3 expression displayed a dramatically poor OS and DFS. The 1-year OS estimate is 0% for patients expressing high levels of FLT3 compared with 71% for patients displaying low-level FLT3 expression (P ¼ 0.002; Figure 2c ). Similarly, the 1-year DFS estimate is 0% for patients expressing high levels of FLT3 compared with 43% for patients displaying low-level FLT3 expression (P ¼ 0.032; Figure 2d ). In contrast, for MLL-germline ALLs the 5-year OS and DFS estimates are 83% and 92%, respectively, for patients expressing high levels of FLT3 compared with 63% and 54%, respectively, for patients displaying low-level FLT3 expression (OS: P ¼ 0.22; DFS: P ¼ 0.1; Figures 2e and f) . Together, FLT3 expression is a robust negative prognostic factor only in MLL-AF4 þ B-ALL cases.
Relevant clinical-biological features were analyzed and compared between the FLT3-high and -low ALL subgroups (Supplementary Table S1 ). For MLL-germline ALL cases, none of the clinical-biological features studied differed between FLT3-high and -low subgroups (P40.1; Supplementary Table S1 ). In contrast, within the MLL-AF4 þ ALL group patients expressing high levels of FLT3 exhibited a significantly lower rate of complete remission Abbreviations: B-ALL, B-acute lymphoblastic leukemia; ITD, internal tandem duplication; T-ALL, T-acute lymphoblastic leukemia; TKD, tyrosine kinase domain. *FLT3 gene expression measured relative to normal bone marrow and normalized against ABL housekeeping gene. **FLT3 mutations analyzed were FLT3 ITD or the punctual mutations in the kinase domain (TKD) D835 and I836. ***All B-ALL patients harboring the t(9;22) do express the BCR-ABL isoform p190. (57% vs 100%; P ¼ 0.038) and lower survival (50% vs 100%; P ¼ 0.029). /l (Po0.0001), 450% blast cells in PB (P ¼ 0.003), platelet count o56 Â 10 9 /l (P ¼ 0.01), B-ALL cytogenetic subtype (ETV6-RUNX1 negative (P ¼ 0.002) and MLL-AF4-positive (Po0.0001)) and high expression of FLT3 (75th percentile, P ¼ 0.008) ( Table 2) . When these variables were entered into a multivariate analysis using a Cox regression model, only age 414 years (Po0.0001) and high FLT3 expression (P ¼ 0.007) retained independent prognostic values for a shorter OS (Table 2 ), which was also confirmed when they were analyzed as continuous variables (P ¼ 0.001; data not shown).
Because FLT3 expression level was a very robust prognostic factor for both OS and DFS in the MLL-AF4 þ B-ALL subgroup but not in MLL-germline ALL (Figure 2) , we analyzed the influence of FLT3 expression on OS and DFS in the context of other clinicobiological risk factors specifically in the MLL-AF4 þ ALL subgroup (n ¼ 15). Interestingly, univariate analysis with OS and DFS as end points showed that high expression of FLT3 (median, P ¼ 0.002 for OS and P ¼ 0.03 for DFS) was the only independent prognostic factor for shorter OS and poorer treatment outcome (Table 3) .
DISCUSSION
Several studies have shown that activating mutations of FLT3 are common in AML. [9] [10] [11] However, the presence of such mutations among different subtypes of ALL remains controversial. Several groups reported the presence of FLT3-TKD or FLT3-ITD mutations in 3-25% of MLL-rearranged or hyperdiploid ALL, 6,12-14 whereas Stam et al. 15, 16 and Bardini et al. 17, 18 , using high-resolution genomic analysis, showed that FLT3 mutations in MLLrearranged ALL do not occur. Despite this controversy, gene expression studies revealed that FLT3 is highly expressed in MLLrearranged ALL, and therefore it still needs to be defined whether the constitutive activation of FLT3 in MLL-rearranged ALL is a direct effect of the presence of FLT3-activating mutations. In the present study, 54 out of 54 (100%) de novo cytogenetically distinct B-ALL and T-ALL lacked FLT3-TKD point mutations (D835Y or I836del) and FLT3-ITD. Thesedata are in line with Stam et al., 15, 16 suggesting that activating FLT3 mutations do not seem to contribute to ALL pathogenesis. In addition, FLT3 gene expression was analyzed in cytogenetically distinct subgroups of ALLs and T-ALL. T-ALLs and E2A-PBX1 þ B-ALL lacked activation of FLT3. In contrast, the remaining cytogenetic subgroups of ALL, especially the MLL-AF4 þ pro-B ALL (37-fold increase), exhibited a significantly higher FLT3 expression levels as compared with NBM. This increased FLT3 expression in the absence of FLT3-activating mutations suggests that the constitutive overexpression of FLT3 is a result of aberrantly increased transcription of FLT3 and it is not due to FLT3-activating mutations. This is supported by Guenther et al., 19 who showed through elegant studies that FLT3 may be a direct target of MLL-AF4. We have analyzed the most common FLT3 mutations found in acute leukemia but have not sequenced the entire FLT3 coding sequence, and therefore, although unlikely, 15 the presence of novel FLT3-activating mutations responsible for constitutive activation of FLT3 might not be completely excluded.
The confirmation that MLL-AF4 þ pro-B ALL patients do not carry FLT3 mutations but display a constitutive transcriptional activation of FLT3 may have relevant implications for the development of MLL-AF4 þ disease models. Leukemia is generally studied once the full transformation events have already occurred and therefore, the mechanisms by which MLL-AF4 transforms to a Variables were dichotomized based on the median value.
c For FLT3 gene expression, the quartile providing the best separation of survival curves (lowest P-value) is shown. In the univariate analysis the log-rank test was used. Multivariate analysis (Cox regression model) was performed by including those clinicobiological features with a P-valueo0.1 in the univariate analysis. Only variables with a P-valueo0.05 were considered as having an independent prognostic value. *In adverse ALL subtypes the survival percentage was calculated for 1 year. P-value for FLT3 expression is shown in bold. pre-leukemic state followed by rapid transition to overt ALL are not amenable to analysis with patient samples. Most of our understanding of transformation by MLL-AF4 has come from murine models [2] [3] [4] 26, 27 and human stem cell systems. 1, [28] [29] [30] [31] [32] [33] These have provided important insights into the likely mode of action of MLL-AF4, but the in vivo leukemias produced in these studies do not recapitulate the actual human disease phenotype and latency, and therefore MLL-AF4 leukemogenesis remains particularly difficult to model. This suggests that in order to develop a bona fide MLL-AF4 model by which to further understand the disease pathogenesis and to screen novel small-molecule compounds, additional oncogenic events such as FLT3 constitutive activation 8 or the derivative AF4-MLL seem to be required to develop ALL. 26 The very high FLT3 mean expression in MLL-AF4 þ ALL patients coupled to the high variability (3.5-to 110-fold expression) suggests the possibility that the FLT3 expression level may have a prognostic significance in MLL-AF4 þ ALL. To analyze the prognosis of our ALL cohort in relation to FLT3 expression, the median FLT3 expression was used as the cut-off value to divide patients into two subgroups expressing high or low levels of FLT3. High-level FLT3 expression is associated with an extremely poor 1-year OS (0 vs 71%) and DFS (0 vs 43%) in MLL-AF4 þ B-ALL but not in any other MLL-germline B-ALL. The presence of BCR-ABL fusion is associated with poor-prognosis B-ALL. In this study, BCR-ABL þ B-ALL also displayed a shorter OS, which was not statistically significant (P ¼ 0.14) probably owing to the small cohort ( Table 2 ). The prognostic value of FLT3 expression was determined in the context of other clinical-biological risk factors in ALL. Cox regression analysis showed that age414 years and high-level FLT3 expression were independent prognostic factors for OS when all ALL patients were analyzed together. Importantly, when the MLL-AF4 þ B-ALL subgroup was analyzed separately, high-level FLT3 expression was the only independent prognostic factor for OS and treatment outcome. These findings indicate that high FLT3 expression identifies MLL-AF4 þ ALL patients at very high risk of treatment failure and poor survival. To the best of our knowledge, this is the first study demonstrating the usefulness of FLT3 expression in improving patient risk stratification in patients suffering from MLL-AF4 þ B-ALL. Previously, Stam et al. 16 have found that high-level FLT3 expression is likely associated with a poor treatment outcome in MLL-rearranged ALL. Our work expands current knowledge because: (i) our cohort specifically comprises MLL-AF4 þ patients and no other MLL rearrangements, (ii) OS was used as end-point analysis besides DFS for patient risk stratification, (iii) our MLL-AF4 þ cohort is composed of both infants and adult patients, indicating that high-level FLT3 expression and the lack of FLT3 mutations are hallmark not only in infants but also in adults with MLL-AF4 þ pro-B ALL, and (iv) Cox regression multivariate analysis reveals that high-level FLT3 expression is an independent prognostic factor when compared with other clinical-biological risk factors in MLL-AF4 þ ALL. The existence of two distinct subgroups among t(4;11)-positive infant ALL cases characterized by the absence or presence of HOXA expression, and that patients lacking HOXA gene expression are at high risk of disease relapse were reported. 34 Future work should be conducted to determine whether there is any biochemical link between HOXA and FLT3 gene expression, and to decipher whether MLL-AF4 þ ALL patients at extremely high risk of relapse and very short OS represent the same cohort displaying high-level FLT3 and lacking HOXA expression, thus providing important novel For FLT3 gene expression, the quartile providing the best separation of survival curves (lowest P-value) is shown. In the univariate analysis the log-rank test was used. Multivariate analysis (Cox regression model) was not performed because FLT3 expression was the only variable with prognostic significance in the univariate analysis. Only variables with a P-valueo0.05 were considered as having an independent prognostic value. P-value for FLT3 expression is shown in bold.
insights into the complex biology of MLL-AF4 þ ALL and boosting our progress in finding novel therapeutic approaches. In this sense, our data support that FLT3 may be a therapeutic target in MLL-AF4 ALL, emphasizing the value of ongoing and future clinical trials for FLT3 inhibitors in infants and adults with MLL-AF4 þ pro-B ALL. 5 
